Beckley Psytech Limited

Industry

  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Nasal
    • Specialty Pharmaceuticals
  • Biotechnology

Other Names/Subsidiaries

  • Eleusis
See more in Biomedtracker

Latest on Beckley Psytech Limited

Scrip

GH’s Phase IIb Data Show Potential Differentiation In Depression

 
• By Joseph Haas

GH Research PLC reported positive Phase IIb data on 3 February for GH-001 (mebufotenin), an inhalation formulation of the psychedelic compound synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), i

Scrip

Beckley Psytech Takes Another Step Toward Psychedelic Antidepressants

 
• By Alaric DeArment

Beckley Psytech Limited bolstered its case for psychedelic treatment of depression with Phase IIa data released as the company runs a separate Phase IIb study that it calls the largest US Food and Dr

Pink Sheet

Lykos’ MDMA NDA Leads Upcoming Tests Of US FDA’s Psychedelics Draft Guidance

 
• By Bridget Silverman

The US FDA will face some crucial tests for its nascent approach to regulation of psychedelic drug candidates in the coming year, headlined by an 11 August 2024 user fee goal for the first psychedelic

Scrip

Deal Watch: Novo Nordisk Builds On Metabolic Strength Acquiring Partner Embark

 
• By Joseph Haas and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk Brings Embark Home After F